Summary & Overview
CPT 0553U: Preimplantation Genetic Testing (Smart PGT–A Plus)
CPT code 0553U designates a Proprietary Laboratory Analyses (PLA) test — Smart PGT–A Plus — used in preimplantation genetic testing of IVF embryos to detect chromosomal abnormalities across 24 chromosomes and provide a mitochondrial DNA score. This PLA code applies only to the specific test offered by Igenomix®, part of Vitrolife Group™, and Thermo Fisher Scientific, making it uniquely identifiable in claims and coverage reviews. Nationally, PLA codes like 0553U are important because they link reimbursement and coverage determinations to a single manufacturer’s assay, affecting access and fee schedules for fertility clinics and patients seeking embryo aneuploidy assessment.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise clinical context for the assay, expected site-of-service considerations, and an outline of payer relevance. The publication summarizes benchmark issues and policy considerations that commonly arise with PLA tests: single-source code implications, coverage variability among major payers, and how the test’s clinical scope (chromosome copy-number, structural rearrangements, mosaicism, mitochondrial DNA scoring) informs medical necessity discussions.
The report provides a national-level overview useful to billing staff, fertility program administrators, and policy analysts seeking clarity on how CPT code 0553U maps to clinical service, payer attention, and claims processing challenges. Data not available in the input will be noted where applicable.
Billing Code Overview
CPT code 0553U is a Proprietary Laboratory Analyses (PLA) code for the Smart PGT–A Plus test marketed by Igenomix®, part of Vitrolife Group™, and Thermo Fisher Scientific. The test evaluates trophectoderm biopsy samples from in vitro fertilization (IVF) embryos for chromosomal abnormalities across 24 chromosomes and reports chromosome copy-number status, structural rearrangements, mosaicism, and a mitochondrial DNA score. Results identify embryos with normal chromosomal complements or specific abnormalities.
Service Type: Genetic/embryo diagnostic laboratory testing (preimplantation genetic testing for aneuploidy)
Typical Site of Service: Specialty molecular or reproductive genetics laboratories supporting assisted reproductive technology (ART) centers and fertility clinics
Clinical & Coding Specifications
Clinical Context
A 36-year-old patient undergoing in vitro fertilization (IVF) elects preimplantation genetic testing for aneuploidy using the proprietary Smart PGT–A Plus assay (0553U) offered by Igenomix® (Vitrolife Group™) and Thermo Fisher Scientific. After ovarian stimulation, oocyte retrieval, fertilization and culture to the blastocyst stage (day 5–7), a trophectoderm biopsy is performed by the reproductive endocrinology laboratory. The sampled cells are placed in appropriate transport media and sent to the laboratory performing the Smart PGT–A Plus test.
The laboratory receives the specimen, extracts DNA, and performs comprehensive chromosome screening across 24 chromosomes including assessment for structural rearrangements, whole-chromosome gains or losses, and mosaicism. The assay also reports a mitochondrial DNA score. Results are returned to the ordering reproductive endocrinologist and the patient’s IVF care team to inform embryo selection for transfer or cryopreservation.
Typical site of service: outpatient fertility clinic and specialized molecular genetics laboratory. The service type is specialized molecular diagnostic testing (Proprietary Laboratory Analysis) specific to a manufacturer’s assay. Clinical workflow steps include: embryo biopsy at the IVF clinic, specimen transport to the performing lab, laboratory genomic analysis, and reporting of embryo chromosomal status to the IVF team for transfer planning.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard service | Use when the test is billed without any special circumstances or adjustments. |
22 | Increased procedural services | Use when extraordinary work, interpretation, or reporting beyond the usual test complexity is documented and justifies increased payment. |
52 | Reduced services | Use when the test is partially performed or a reduced service is provided and documented (for example, limited panel due to insufficient sample). |
53 | Discontinued procedure | Use when testing is started but discontinued for documented clinical or technical reasons prior to completion. |
26 | Professional component | Use when billing the professional component (interpretation) separately from the technical component performed by the lab. |
TC | Technical component | Use when billing only the technical component (laboratory processing and analysis) and the ordering clinician bills separately for professional interpretation. |
59 | Distinct procedural service | Use when this lab test is distinct and separate from other services on the same date that might otherwise be bundled. |
QW | CLIA-waived test | Not typically applicable; include only if regulatory status or payer instructions require identifying waived tests. |
90 | Reference (outside) lab | Use when the performing lab bills on behalf of another provider or when specimen is sent to an outside reference laboratory and billing requires this indicator. |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
207RC0000X | Reproductive Endocrinology and Infertility | Specialists who order embryo biopsy and coordinate IVF treatment. |
207K00000X | Obstetrics & Gynecology | OB/GYNs involved in fertility care and IVF programs. |
208100000X | Clinical Molecular Genetics Laboratory | Laboratories and laboratory directors responsible for performing proprietary genetic assays. |
261QM2500X | Clinical Genetics | Clinical geneticists who may interpret complex genetic findings and counsel patients. |
2085R0200X | Molecular Pathology | Pathology specialists overseeing molecular diagnostic testing and quality control. |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
Z31.41 | Encounter for assisted reproductive fertility procedure cycle, completed | Relevant for patients undergoing an IVF cycle in which embryo biopsy and 0553U testing are performed. |
Z31.42 | Encounter for assisted reproductive fertility procedure cycle, initiated | Relevant when the IVF cycle is initiated and planning includes preimplantation genetic testing. |
N97.9 | Female infertility, unspecified | Common indication for IVF and preimplantation genetic testing to improve pregnancy outcomes. |
O09.93 | Supervision of high-risk pregnancy, unspecified trimester | May be relevant when prior reproductive history or genetic findings increase pregnancy risk and IVF with PGT is used to reduce risk. |
Z31.49 | Encounter for other assisted reproductive fertility procedure | Catch-all code used for related fertility procedures associated with embryo testing and transfer. |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
89260 | Embryo biopsy, blastocyst (trophectoderm), with or without zona pellucida manipulation | Performed at the IVF clinic to obtain the trophectoderm sample that is sent for 0553U testing. |
89250 | Semen and/or ovum preparation for assisted reproductive technology; microinjection (ICSI) | Performed earlier in the IVF cycle as part of fertilization procedures preceding embryo biopsy and genetic testing. |
88271 | Molecular cytogenetics; FISH, 1–2 probes | May be used for confirmatory or alternative chromosome analysis in specific cases; not a substitute for comprehensive chromosome screening provided by 0553U. |
81479 | Unlisted molecular pathology procedure | Occasionally used when billing unique or additional molecular tests not otherwise described, but proprietary PLA 0553U is preferred for the Smart PGT–A Plus assay. |
88384 | Consultation and interpretation; complex molecular pathology consult | Used when a separate, complex professional interpretation or consultation is performed related to genetic test results for embryo selection. |